



NGL Fine-Chem Ltd

Earnings Presentation Q1 22-23

Disclaimer

This presentation and the accompanying slides (the "Presentation"), which have been prepared by NGL Fine-Chem Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guaranteeing of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.





Q1/FY23 Highlights of the Year



Year in review

0

Business Environment

Demand in key markets subdued during Q1 22-23, however customer retention still high

•Macro factors pushed input costs to new highs during the year, while fuel and freight also impacted product supply and margins

•Trends of price increase are now easing with expectation of this reduction continuing in current quarter.

Products

65%+ capacity utilization (incl new Mactrotech expansion) during the quarter on account of subdued demand

•Macrotech expansion completed during the year, approvals in place and validation batches almost completed at facility

•Civil construction started in December 2021 at Tarapur for the planned greenfield expansion

Operations

Subdued demand witnessed during the year in Anthelmentics and Antiparasitics, top 5 products saw reduction in demand

•New molecules streamlined and 2 new products pilot trials completed in current quarter.

Financial

•Decrease in sales of 16% YoY in Q1 & 22% sequentially, due to lower demand for top 5 products

•Continuing trend of rising costs (fuel & commodity) severely impacted margins and profitability

•Strong balance sheet with net debt free position to support investments in capex and greenfield expansion



Consolidated profit & loss statement



Rupees lakhs	Q1 22-23	Q4 21-22	Change	Q1 21-22
Revenue Income	67.75	87.04	-22.16%	80.41
Cost of Material Consumed	35.24	39.93		32.26
Gross Profit	32.51	47.11	-30.99%	48.15
Gross Profit Margin (%)	48.0%	54.1%		59.9%
Employee Expenses	8.90	9.27		7.46
Other Expenses	18.96	24.30		12.58
EBITDA	4.65	13.54	-65.66%	28.11
EBITDA Margin (%)	6.9%	15.6%	05.0070	35.0%
0 ()				
Finance Cost	0.50	1.54		0.37
Depreciation	3.60	3.48		2.18
	5.00	5.40		2.10
Profit Before Tax	0.55	8.52		25.56
PBT %	0.8%	9.8%	-91.84%	31.8%
Taxes	-0.03	-1.66		-6.44
Profit After Tax	0.52	6.86		19.12
PAT %	0.8%	7.9%	-89.87%	23.8%



Segment distribution



Q1 FY23 Revenue Distribution Q1 22-23 FORMULATIONS HUMAN API 5% 4% OTHERS 3% VET API 88%

• VET API • OTHERS • HUMAN API • FORMULATIONS

Rupees Crores	Q1 22-23	Q1 21-22	Change	Q4 21 -22
VET API	55.41	57.51	-3.79%	66.19
OTHERS	1.94	12.73	-556.19%	4.22
HUMAN API	2.62	3.26	-24.43%	6.65
FORMULATIONS	2.76	2.99	-8.33%	1.06

Standalone financials




Regional distribution



7

Q1 22-23 Revenue Distribution



Revenue (Rs Cr)	Q1 22-23	Q4 21-22	Change	FY 22
Asia	22.6	19.0	19%	93.8
Europe	15.8	22.0	-28%	87.2
India	16.5	23.2	-29%	76.3
ROW	9.5	8.5	12%	47.2
USA	0.1	3.1	-98%	9.8





8

Overview, Key Strengths and Strategy



Leading animal health company





Humit	Comprehensive product portfolio	 24 APIs (22 veterinary API, 2 human), 4 intermediates, 10 finished dosage forms Best quality and value-driven pricing
	Market leadership in vet API	 Leadership in top 5 products – 50%+ market share Growing position in next 4 – taking market share from other players
	Manufacturing excellence	 3 state of the art manufacturing facilities Strong R&D capabilities in custom synthesis
	Large global presence	 45+ countries across the globe with country-wise regulatory approvals Strong presence in unregulated markets
	Long standing customer relationships	 ~400 customers Reliable supplier focused on good sale support to all customers

Leadership in veterinary API segment



Wide Range of Product Categories Strong controls of processes with High quality and reliable Anthelmintics **95%** in-house manufacturing and products with no market rejection backward integrated facilities in 15 years leading to cost competitiveness Ectoparasiticides Antiprotozoals Market share ranging from 15% Suppliers to **5 of top 10** global to 50%+ in key products animal healthcare companies Phosphorus Supplements





State-of-the-art manufacturing capabilities



3 manufacturing facilities located at Tarapur & Navi Mumbai, Maharashtra, designed to meet the requirements of regulatory agencies and are capable of a wide range of reaction capabilities

10,000 m2 Area of manufacturing facilities	102 m3 Glass-lined reactors	194 m3 Stainless steel reactors	75%	Production coming from Zero Liquid Discharge facilities
12 m3	-20 ⁰ C to +250 ⁰ (C		Discharge rachines
Gas induction reactors	Reaction range		cio	REACH
			UKAS	2****







Accreditations

WHO-GMP, ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and cGMP accredited

Advantageously placed in a growing opportunity



	Market Size 2020	Market Size 2027	Segment Trends	Growth Drivers	
Animal Health Market	\$139 Billion	\$192 Billion (CAGR – 4.7%)	 Pharma segment to grow at higher rate – 5.4% CAGR Production animal segment have the larger pie 	 Rising prevalence of zoonotic diseases, animal population & pet ownership Global livestock 	
				population has been experiencing rapid	
Animal API Market	\$6.6 Billion	\$10.5 Billion (CAGR – 6.9%)	 APAC market to grow at higher rate – 7.3% CAGR Antiparasitics API fastest growing segment 	growth High demand for animal- based products and growing meat consumption 	

Source: Grand View Research & Global Market Insights




Strategy for next leg of growth

0

13

Ongoing initiatives to increase capacities to meet growing demand



Greenfield expansion at Tarapur

Larger expansion to drive the next leg of exponential growth



- 50% capacity expansion with sufficient capacity to meet demand for new products in pipeline
- Estimated capex of Rs 140 cr to be funded through debt and internal accrual; incurred capex of Rs 7 cr so far
- Civil construction undergoing, facility expected to commercialize in FY24. Currently implementation is slowed down in view of high commodity prices











Robust financial performance










Improving efficiencies





ROCE = EBIT / Avg Capital Employed (Shareholder's Fund + Total Debt) Debt/Equity = Total Debt / Shareholder's Fund FATO = Revenue / Fixed Assets (Inc CWIP)



Thank You



NGL Fine-Chem Ltd

Pallavi Pednekar (Company Secretary) <u>cs@nglfinechem.com</u>